Distinguished Professor of Pharmacology and Pathology
Ph.D., University of California, Los Angeles
Key Words: Gene Expression, Signal Transduction, Transcription Factors, Oncogenes, Protein Kinases
Dr. Karin was born in Tel Aviv, Israel and received the Bachelor of Science degree in 1975 from Tel Aviv University, with a major in Biology. In 1975 he arrived in the US and in 1979 received a Ph.D. degree in Molecular Biology from the University of California, Los Angeles. Dr. Karin followed his graduate studies with postdoctoral fellowships at the Fox Chase Institute for Cancer Research, working in the laboratory of Dr. Beatrice Mintz, and the laboratory of Dr. John Baxter at the University of California, San Francisco. Dr. Karin joined the faculty at the University of California, San Diego in 1986, where currently he is a Distinguished Professor of Pharmacology.
Dr. Karin has received numerous awards including the Oppenheimer Award for Excellence in Research from the Endocrine Society, The Herman Beerman Lectureship from the Society of Investigative Dermatology, C.E.R.I.E.S. Research Award for Physiology or Biology of the Skin, The Grossman Lectureship form the American Gastroenterology Association and an American Cancer Society Research Professorship in 1999. Dr. Karin was elected to the National Academy of Sciences in 2005. Dr. Karin also serves on several advisory boards and was cofounder of Signal Pharmaceuticals (currently Celgene).
My laboratory is investigating mechanisms by which extracellular stimuli regulate expression of mammalian genes and modulate proliferation, diff erentiation and survival of diff erent cell types. We focus on both transcriptional and posttranscriptional control mechanisms and are mostly interested in the role of protein kinases and other signaling molecules in these regulatory processes. Much of the current research deals with the response of mammalian cells to pro-inflammatory stimuli, diff erent fi rms of radiation and oxidative stress. We are particularly interested in the signaling mechanisms used by tumor necrosis factor (TNF), interleukin 1 (IL-1) and other infl ammatory cytokines to promote tumor development and progression. In recent years we have been studying how these pathways link chronic infl ammation and obesity to cancer development in organs such as the liver and pancreas. The lab is using a variety of approaches spanning the entire spectrum from protein purifi cation to the generation and analysis of mutant mouse strains.
Lee, J.H., Budanov, A.V., Park, E.J., Birse, R., Kim, T.E., Perkins, G.A., Ocorr, K., Ellisman, M.H., Bodmer, R., Bier, E., Karin, M. (2010) Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 327:1223-1228. PMCID: PMC2866632
Holzer, R.G., Pa rk, E.-J., Li, N., Tran, H., Chen, M., Choi, C., Solinas, G., Karin, M. (2011) Saturated fatty acids induce c-Src clustering within membrane subdomains leading to JNK activation. Cell 147:173-184. PMCID: PM C3295636
Grivennikov, S., Wang, K., Mucida, D., Stewart, C-A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G., Österreicher, C.H., Hung, K.E., Datz, C., Feng, Y., Fearon, E.R., Oukka, M., Tessarollo, L., Coppola, V., Yarovinsky, F., Cheroutre, H., Eckmann, L., Trinchieri, G., Karin, M. (2012) Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 7423: 254-8. PMID: 23034650
He, G., Dhar, D., Nakagawa, H., Font-Burgada, J., Ogata, H., Jiang, Y., Shalapour, S., Seki, E., Yost, S., Jepsen, K., Frazer, K., Harismendy, O., Hatziapostolou, M., Iliopoulos, D., Suetsugu, A., Hoff man, R., Tateishi, R., Koike, K., Karin, M. (2013) Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell in press